Mizuho reiterated their buy rating on shares of Amgen Inc. (NASDAQ:AMGN) in a report issued on Friday, October 6th. They currently have a $198.00 price objective on the medical research company’s stock.
A number of other equities analysts have also commented on the company. Morgan Stanley reissued an overweight rating and set a $196.00 price target (up from $189.00) on shares of Amgen in a research note on Friday, October 6th. Cann reaffirmed a buy rating and issued a $203.00 price objective on shares of Amgen in a research note on Friday, October 6th. Bank of America Corporation raised their price objective on Amgen to $210.00 and gave the company a buy rating in a research note on Thursday, October 5th. Credit Suisse Group reiterated a neutral rating and issued a $186.00 price target (up from $177.00) on shares of Amgen in a report on Friday, September 29th. Finally, Jefferies Group LLC reiterated a buy rating and issued a $200.00 price target on shares of Amgen in a report on Monday, September 25th. Twelve analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $189.99.
Amgen (NASDAQ AMGN) opened at 186.28 on Friday. The firm has a market cap of $135.92 billion, a P/E ratio of 16.97 and a beta of 1.36. Amgen has a 52 week low of $133.64 and a 52 week high of $191.10. The firm’s 50-day moving average price is $184.68 and its 200 day moving average price is $171.37.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. During the same period in the prior year, the company earned $2.84 earnings per share. The firm’s revenue was up 2.1% on a year-over-year basis. Equities analysts forecast that Amgen will post $12.58 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Amgen’s (NASDAQ:AMGN) Buy Rating Reiterated at Mizuho” was originally published by BBNS and is owned by of BBNS. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://baseballnewssource.com/markets/amgen-inc-amgn-receives-buy-rating-from-mizuho/1703246.html.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $185.95, for a total transaction of $283,573.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.19% of the stock is currently owned by insiders.
A number of large investors have recently bought and sold shares of AMGN. Waldron LP purchased a new stake in Amgen during the 1st quarter worth approximately $444,000. Acadian Asset Management LLC increased its stake in Amgen by 81.0% during the 1st quarter. Acadian Asset Management LLC now owns 4,770 shares of the medical research company’s stock worth $784,000 after buying an additional 2,135 shares in the last quarter. Meritage Portfolio Management increased its stake in Amgen by 0.5% during the 1st quarter. Meritage Portfolio Management now owns 45,730 shares of the medical research company’s stock worth $7,503,000 after buying an additional 230 shares in the last quarter. NBT Bank N A NY increased its stake in Amgen by 19.9% during the 1st quarter. NBT Bank N A NY now owns 5,565 shares of the medical research company’s stock worth $913,000 after buying an additional 925 shares in the last quarter. Finally, Mycio Wealth Partners LLC increased its stake in Amgen by 6.9% during the 1st quarter. Mycio Wealth Partners LLC now owns 5,594 shares of the medical research company’s stock worth $918,000 after buying an additional 363 shares in the last quarter. Institutional investors own 78.08% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with our FREE daily email newsletter.